Growing Dicerna moves into Cambridge supercluster

Dicerna CEO Douglas Fambrough

Now that Dicerna has cashed in on the biotech IPO gold rush, the biotech ($DRNA) has moved closer to where the action is. Local VIPs are gathering this morning to cut the ribbon on the biotech's new 37,000-square-foot office and R&D center in Cambridge. The 2010 Fierce 15 company--which moved in from nearby Watertown--has been raking in cash while enjoying some rising expectations for RNAi. "Dicerna has more than doubled its footprint in the new space and now employs approximately 45 people, with plans to hire an additional 10 employees this year, and many more going forward," says Dicerna CEO Douglas Fambrough. Release

Suggested Articles

EQRx is adding a pair of PD-1/PD-L1 meds to its pipeline through a deal with CStone worth $150 million upfront but could net the latter $1.15 billion.

All eyes are on Pfizer’s COVID-19 vaccine work, but the Big Pharma has today quietly culled two midstage trials and one phase 1 test.

All subjects had lower extremity weakness after receiving antisense oligonucleotide GTX-102, leading Ultragenyx to pause the study.